← Back to patent-cliff list
CAS 2873-29-2
(2R,3S,4R)-3,4-Diacetoxy-3,4-dihydro-2H-pyran-2-yl]methyl acetate
Codes: (I)101438-55-a
Application context (from source-drug indications)
Breast cancerPaclitaxel/Encequidar mesylateAdenocarcinomaPaclitaxel/Encequidar mesylateAngiosarcomaPaclitaxel/Encequidar mesylateSolid tumourPaclitaxel/Encequidar mesylatePancreatic cancerPaclitaxelNon-small cell lung cancerPaclitaxelHodgkin's diseasePaclitaxelSeminomaPaclitaxelOvarian cancerPaclitaxelBreast cancerPaclitaxel
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Paclitaxel/Encequidar mesylate | Tier C — Watch / trade | - |
| Paclitaxel | Tier B — Position early | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
(2R,3S,4R)-3,4-Diacetoxy-3,4-dihydro-2H-pyran-2-yl]methyl acetate→Methyl 4,6-di-O-acetyl-2,3-dideoxy-alpha-D-erythro-hex-2-enopyranoside→Methyl 4,6-di-O-acetyl-2,3-dideoxy-alpha-D-erythro-hexopyranoside→Methyl 2,3-dideoxy-alpha-D-erythro-hexopyranoside→(6S)-6-(Benzyloxy)cyclohex-2-en-1-one→(2S,3S,6S)-2-(Iodomethyl)-6-methoxytetrahydro-2H-pyran-3-ol→(2S,3S,6S)-3-(Benzyloxy)-2-(iodomethyl)-6-methoxytetrahydro-2H-pyran→(3S,6S)-3-(Benzyloxy)-6-methoxy-2-methylenetetrahydro-2H-pyran→(2S,5R)-2-(Benzyloxy)-5-hydroxycyclohexanone→lithium carbanide→(6S)-6-(Benzyloxy)-1-methylcyclohex-2-en-1-ol→(4S)-4-(Benzyloxy)-3-methylcyclohex-2-en-1-one→Chloro(ethynyl)magnesium→Formaldehyde→(2R,3S,4S)-4-(Benzyloxy)-2-(hydroxymethyl)-3-methyl-3-vinylcyclohexanone→(2R,3S,4S)-4-(Benzyloxy)-3-methyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]-3-vinylcyclohexanone→(1S,2R,3S,4S)-4-(Benzyloxy)-3-methyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]-3-vinylcyclohexanol→2-[[(1R,2S,3S,6S)-3-(Benzyloxy)-6-(methoxymethoxy)-2-methyl-2-vinylcyclohexyl]methoxy]tetrahydro-2H-pyran
(2R,3S,4R)-3,4-Diacetoxy-3,4-dihydro-2H-pyran-2-yl]methyl acetate→Methyl 4,6-di-O-acetyl-2,3-dideoxy-alpha-D-erythro-hex-2-enopyranoside→Methyl 4,6-di-O-acetyl-2,3-dideoxy-alpha-D-erythro-hexopyranoside→Methyl 2,3-dideoxy-alpha-D-erythro-hexopyranoside→(6S)-6-(Benzyloxy)cyclohex-2-en-1-one→(2S,3S,6S)-2-(Iodomethyl)-6-methoxytetrahydro-2H-pyran-3-ol→(2S,3S,6S)-3-(Benzyloxy)-2-(iodomethyl)-6-methoxytetrahydro-2H-pyran→(3S,6S)-3-(Benzyloxy)-6-methoxy-2-methylenetetrahydro-2H-pyran→(2S,5R)-2-(Benzyloxy)-5-hydroxycyclohexanone→lithium carbanide→(6S)-6-(Benzyloxy)-1-methylcyclohex-2-en-1-ol→(4S)-4-(Benzyloxy)-3-methylcyclohex-2-en-1-one→Chloro(ethynyl)magnesium→Formaldehyde→(2R,3S,4S)-4-(Benzyloxy)-2-(hydroxymethyl)-3-methyl-3-vinylcyclohexanone→(2R,3S,4S)-4-(Benzyloxy)-3-methyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]-3-vinylcyclohexanone→(1S,2R,3S,4S)-4-(Benzyloxy)-3-methyl-2-[(tetrahydro-2H-pyran-2-yloxy)methyl]-3-vinylcyclohexanol→2-[[(1R,2S,3S,6S)-3-(Benzyloxy)-6-(methoxymethoxy)-2-methyl-2-vinylcyclohexyl]methoxy]tetrahydro-2H-pyran
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.